Cancer-Cell-Intrinsic Mechanisms Shaping the Tumor Immune Landscape

Immunity

Volumn 48, Issue 3, 2018, Pages 399-416

  Wellenstein, Max D ^a   de Visser, Karin E ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B; PROTEIN P53; BIOLOGICAL MARKER;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; GENE TARGETING; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; INFLAMMATION; INTRINSIC ACTIVITY; LYMPH NODE METASTASIS; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REVIEW; SENESCENCE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ANIMAL; CELL TRANSFORMATION; DISEASE PREDISPOSITION; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION STUDY; GENETIC PREDISPOSITION; GENETICS; IMMUNE SYSTEM; IMMUNOLOGY; IMMUNOMODULATION; METABOLISM; NEOPLASM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; BIOMARKERS; CELL TRANSFORMATION, NEOPLASTIC; DISEASE SUSCEPTIBILITY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNE SYSTEM; IMMUNOMODULATION; NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 85043767157     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2018.03.004     Document Type: Review

References (125)

1. Adams, J.M., Harris, A.W., Pinkert, C.A., Corcoran, L.M., Alexander, W.S., Cory, S., Palmiter, R.D., Brinster, R.L., The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318 (1985), 533–538.
2. Akbay, E.A., Koyama, S., Carretero, J., Altabef, A., Tchaicha, J.H., Christensen, C.L., Mikse, O.R., Cherniack, A.D., Beauchamp, E.M., Pugh, T.J., et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 3 (2013), 1355–1363.
3. Ancrile, B., Lim, K.H., Counter, C.M., Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev. 21 (2007), 1714–1719.
4. Bailey, P., Chang, D.K., Nones, K., Johns, A.L., Patch, A.M., Gingras, M.C., Miller, D.K., Christ, A.N., Bruxner, T.J., Quinn, M.C., et al., Australian Pancreatic Cancer Genome Initiative. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531 (2016), 47–52.
5. Balkwill, F., Mantovani, A., Inflammation and cancer: back to Virchow?. Lancet 357 (2001), 539–545.
6. Balli, D., Rech, A.J., Stanger, B.Z., Vonderheide, R.H., Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer. Clin. Cancer Res. 23 (2017), 3129–3138.
7. Becht, E., de Reyniès, A., Giraldo, N.A., Pilati, C., Buttard, B., Lacroix, L., Selves, J., Sautès-Fridman, C., Laurent-Puig, P., Fridman, W.H., Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy. Clin. Cancer Res. 22 (2016), 4057–4066.
8. Beroukhim, R., Mermel, C.H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J.S., Dobson, J., Urashima, M., et al. The landscape of somatic copy-number alteration across human cancers. Nature 463 (2010), 899–905.
9. Bezzi, M., Seitzer, N., Ishikawa, T., Reschke, M., Chen, M., Wang, G., Mitchell, C., Ng, C., Katon, J., Lunardi, A., et al. Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms. Nat. Med. 24 (2018), 165–175.
10. Blaisdell, A., Crequer, A., Columbus, D., Daikoku, T., Mittal, K., Dey, S.K., Erlebacher, A., Neutrophils Oppose Uterine Epithelial Carcinogenesis via Debridement of Hypoxic Tumor Cells. Cancer Cell 28 (2015), 785–799.
11. Boveri, T., Zur Frage der Entstehung Maligner Tumoren. Gustav Fischer 1914 (1914), 1–64.
12. Brandetti, E., Veneziani, I., Melaiu, O., Pezzolo, A., Castellano, A., Boldrini, R., Ferretti, E., Fruci, D., Moretta, L., Pistoia, V., et al. MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastoma. OncoImmunology, 6, 2017, e1316439.
13. Busch, S.E., Hanke, M.L., Kargl, J., Metz, H.E., MacPherson, D., Houghton, A.M., Lung Cancer Subtypes Generate Unique Immune Responses. J. Immunol. 197 (2016), 4493–4503.
14. Casey, S.C., Tong, L., Li, Y., Do, R., Walz, S., Fitzgerald, K.N., Gouw, A.M., Baylot, V., Gütgemann, I., Eilers, M., Felsher, D.W., MYC regulates the antitumor immune response through CD47 and PD-L1. Science 352 (2016), 227–231.
15. Cha, Y.J., Kim, H.R., Lee, C.Y., Cho, B.C., Shim, H.S., Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status. Lung Cancer 97 (2016), 73–80.
16. Charoentong, P., Finotello, F., Angelova, M., Mayer, C., Efremova, M., Rieder, D., Hackl, H., Trajanoski, Z., Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade. Cell Rep. 18 (2017), 248–262.
17. Chen, D.S., Mellman, I., Oncology meets immunology: the cancer-immunity cycle. Immunity 39 (2013), 1–10.
18. + cytotoxic lymphocyte is a favorable prognostic marker in node-negative breast cancer. PLoS ONE, 9, 2014, e95475.
19. Chen, C.F., Ruiz-Vega, R., Vasudeva, P., Espitia, F., Krasieva, T.B., de Feraudy, S., Tromberg, B.J., Huang, S., Garner, C.P., Wu, J., et al. ATR Mutations Promote the Growth of Melanoma Tumors by Modulating the Immune Microenvironment. Cell Rep. 18 (2017), 2331–2342.
20. Chien, Y., Scuoppo, C., Wang, X., Fang, X., Balgley, B., Bolden, J.E., Premsrirut, P., Luo, W., Chicas, A., Lee, C.S., et al. Control of the senescence-associated secretory phenotype by NF-κB promotes senescence and enhances chemosensitivity. Genes Dev. 25 (2011), 2125–2136.
21. Coelho, M.A., de Carné Trécesson, S., Rana, S., Zecchin, D., Moore, C., Molina-Arcas, M., East, P., Spencer-Dene, B., Nye, E., Barnouin, K., et al. Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA. Immunity 47 (2017), 1083–1099.e6.
22. Coffelt, S.B., Wellenstein, M.D., de Visser, K.E., Neutrophils in cancer: neutral no more. Nat. Rev. Cancer 16 (2016), 431–446.
23. Coley, W.B., The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am. J. Med. Sci. 105 (1893), 487–511.
24. Cooks, T., Pateras, I.S., Tarcic, O., Solomon, H., Schetter, A.J., Wilder, S., Lozano, G., Pikarsky, E., Forshew, T., Rosenfeld, N., et al. Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell 23 (2013), 634–646.
25. Cooks, T., Harris, C.C., Oren, M., Caught in the cross fire: p53 in inflammation. Carcinogenesis 35 (2014), 1680–1690.
26. Debebe, A., Medina, V., Chen, C.Y., Mahajan, I.M., Jia, C., Fu, D., He, L., Zeng, N., Stiles, B.W., Chen, C.L., et al. Wnt/β-catenin activation and macrophage induction during liver cancer development following steatosis. Oncogene 36 (2017), 6020–6029.
27. Decker, T., Fischer, G., Bücke, W., Bücke, P., Stotz, F., Grüneberger, A., Gropp-Meier, M., Wiedemann, G., Pfeiffer, C., Peschel, C., Götze, K., Increased number of regulatory T cells (T-regs) in the peripheral blood of patients with Her-2/neu-positive early breast cancer. J. Cancer Res. Clin. Oncol. 138 (2012), 1945–1950.
28. Deng, J., Wang, E.S., Jenkins, R.W., Li, S., Dries, R., Yates, K., Chhabra, S., Huang, W., Liu, H., Aref, A.R., et al. CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. Cancer Discov. 8 (2018), 216–233.
29. Di Mitri, D., Toso, A., Chen, J.J., Sarti, M., Pinton, S., Jost, T.R., D'Antuono, R., Montani, E., Garcia-Escudero, R., Guccini, I., et al. Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer. Nature 515 (2014), 134–137.
30. Diakos, C.I., Charles, K.A., McMillan, D.C., Clarke, S.J., Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 15 (2014), e493–e503.
31. Donehower, L.A., Harvey, M., Slagle, B.L., McArthur, M.J., Montgomery, C.A. Jr., Butel, J.S., Bradley, A., Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356 (1992), 215–221.
32. Dorand, R.D., Nthale, J., Myers, J.T., Barkauskas, D.S., Avril, S., Chirieleison, S.M., Pareek, T.K., Abbott, D.W., Stearns, D.S., Letterio, J.J., et al. Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity. Science 353 (2016), 399–403.
33. Doucette, T., Rao, G., Rao, A., Shen, L., Aldape, K., Wei, J., Dziurzynski, K., Gilbert, M., Heimberger, A.B., Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas. Cancer Immunol. Res. 1 (2013), 112–122.
34. Duesberg, P.H., Vogt, P.K., Differences between the ribonucleic acids of transforming and nontransforming avian tumor viruses. Proc. Natl. Acad. Sci. USA 67 (1970), 1673–1680.
35. Finisguerra, V., Di Conza, G., Di Matteo, M., Serneels, J., Costa, S., Thompson, A.A., Wauters, E., Walmsley, S., Prenen, H., Granot, Z., et al. MET is required for the recruitment of anti-tumoural neutrophils. Nature 522 (2015), 349–353.
36. Fisher, G.H., Wellen, S.L., Klimstra, D., Lenczowski, J.M., Tichelaar, J.W., Lizak, M.J., Whitsett, J.A., Koretsky, A., Varmus, H.E., Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev. 15 (2001), 3249–3262.
37. Frederick, D.T., Piris, A., Cogdill, A.P., Cooper, Z.A., Lezcano, C., Ferrone, C.R., Mitra, D., Boni, A., Newton, L.P., Liu, C., et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin. Cancer Res. 19 (2013), 1225–1231.
38. Garon, E.B., Rizvi, N.A., Hui, R., Leighl, N., Balmanoukian, A.S., Eder, J.P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al., KEYNOTE-001 Investigators. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372 (2015), 2018–2028.
39. Gentles, A.J., Newman, A.M., Liu, C.L., Bratman, S.V., Feng, W., Kim, D., Nair, V.S., Xu, Y., Khuong, A., Hoang, C.D., et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat. Med. 21 (2015), 938–945.
40. Glodde, N., Bald, T., van den Boorn-Konijnenberg, D., Nakamura, K., O'Donnell, J.S., Szczepanski, S., Brandes, M., Eickhoff, S., Das, I., Shridhar, N., et al. Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy. Immunity 47 (2017), 789–802 e789.
41. Goel, S., DeCristo, M.J., Watt, A.C., BrinJones, H., Sceneay, J., Li, B.B., Khan, N., Ubellacker, J.M., Xie, S., Metzger-Filho, O., et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature 548 (2017), 471–475.
42. Groenendijk, F.H., Bernards, R., Drug resistance to targeted therapies: déjà vu all over again. Mol. Oncol. 8 (2014), 1067–1083.
43. Gunderson, A.J., Kaneda, M.M., Tsujikawa, T., Nguyen, A.V., Affara, N.I., Ruffell, B., Gorjestani, S., Liudahl, S.M., Truitt, M., Olson, P., et al. Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer. Cancer Discov. 6 (2016), 270–285.
44. Hanahan, D., Wagner, E.F., Palmiter, R.D., The origins of oncomice: a history of the first transgenic mice genetically engineered to develop cancer. Genes Dev. 21 (2007), 2258–2270.
45. Herranz, N., Gallage, S., Mellone, M., Wuestefeld, T., Klotz, S., Hanley, C.J., Raguz, S., Acosta, J.C., Innes, A.J., Banito, A., et al. mTOR regulates MAPKAPK2 translation to control the senescence-associated secretory phenotype. Nat. Cell Biol. 17 (2015), 1205–1217.
46. Hoare, M., Ito, Y., Kang, T.W., Weekes, M.P., Matheson, N.J., Patten, D.A., Shetty, S., Parry, A.J., Menon, S., Salama, R., et al. NOTCH1 mediates a switch between two distinct secretomes during senescence. Nat. Cell Biol. 18 (2016), 979–992.
47. Hu-Lieskovan, S., Mok, S., Homet Moreno, B., Tsoi, J., Robert, L., Goedert, L., Pinheiro, E.M., Koya, R.C., Graeber, T.G., Comin-Anduix, B., Ribas, A., Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci. Transl. Med., 7, 2015, 279ra41.
48. Hugo, W., Zaretsky, J.M., Sun, L., Song, C., Moreno, B.H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma. Cell 165 (2016), 35–44.
49. Huijbers, I.J., Generating Genetically Modified Mice: A Decision Guide. Methods Mol. Biol. 1642 (2017), 1–19.
50. Jain, M., Arvanitis, C., Chu, K., Dewey, W., Leonhardt, E., Trinh, M., Sundberg, C.D., Bishop, J.M., Felsher, D.W., Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 297 (2002), 102–104.
51. Ji, H., Houghton, A.M., Mariani, T.J., Perera, S., Kim, C.B., Padera, R., Tonon, G., McNamara, K., Marconcini, L.A., Hezel, A., et al. K-ras activation generates an inflammatory response in lung tumors. Oncogene 25 (2006), 2105–2112.
52. Jiang, D., Gao, Z., Cai, Z., Wang, M., He, J., Clinicopathological and prognostic significance of FOXP3+ tumor infiltrating lymphocytes in patients with breast cancer: a meta-analysis. BMC Cancer, 15, 2015, 727.
53. Jiang, H., Hegde, S., Knolhoff, B.L., Zhu, Y., Herndon, J.M., Meyer, M.A., Nywening, T.M., Hawkins, W.G., Shapiro, I.M., Weaver, D.T., et al. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat. Med. 22 (2016), 851–860.
54. Kang, T.W., Yevsa, T., Woller, N., Hoenicke, L., Wuestefeld, T., Dauch, D., Hohmeyer, A., Gereke, M., Rudalska, R., Potapova, A., et al. Senescence surveillance of pre-malignant hepatocytes limits liver cancer development. Nature 479 (2011), 547–551.
55. Kastenhuber, E.R., Lowe, S.W., Putting p53 in Context. Cell 170 (2017), 1062–1078.
56. Katlinski, K.V., Gui, J., Katlinskaya, Y.V., Ortiz, A., Chakraborty, R., Bhattacharya, S., Carbone, C.J., Beiting, D.P., Girondo, M.A., Peck, A.R., et al. Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor Microenvironment. Cancer Cell 31 (2017), 194–207.
57. Keck, M.K., Zuo, Z., Khattri, A., Stricker, T.P., Brown, C.D., Imanguli, M., Rieke, D., Endhardt, K., Fang, P., Brägelmann, J., et al. Integrative analysis of head and neck cancer identifies two biologically distinct HPV and three non-HPV subtypes. Clin. Cancer Res. 21 (2015), 870–881.
58. Kersten, K., de Visser, K.E., van Miltenburg, M.H., Jonkers, J., Genetically engineered mouse models in oncology research and cancer medicine. EMBO Mol. Med. 9 (2017), 137–153.
59. Knudson, A.G. Jr., Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. USA 68 (1971), 820–823.
60. Kobielak, A., Fuchs, E., Links between alpha-catenin, NF-kappaB, and squamous cell carcinoma in skin. Proc. Natl. Acad. Sci. USA 103 (2006), 2322–2327.
61. Kortlever, R.M., Sodir, N.M., Wilson, C.H., Burkhart, D.L., Pellegrinet, L., Brown Swigart, L., Littlewood, T.D., Evan, G.I., Myc Cooperates with Ras by Programming Inflammation and Immune Suppression. Cell 171 (2017), 1301–1315.e14.
62. Koya, R.C., Mok, S., Otte, N., Blacketor, K.J., Comin-Anduix, B., Tumeh, P.C., Minasyan, A., Graham, N.A., Graeber, T.G., Chodon, T., Ribas, A., BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy. Cancer Res. 72 (2012), 3928–3937.
63. Koyama, S., Akbay, E.A., Li, Y.Y., Aref, A.R., Skoulidis, F., Herter-Sprie, G.S., Buczkowski, K.A., Liu, Y., Awad, M.M., Denning, W.L., et al. STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. Cancer Res. 76 (2016), 999–1008.
64. Laberge, R.M., Sun, Y., Orjalo, A.V., Patil, C.K., Freund, A., Zhou, L., Curran, S.C., Davalos, A.R., Wilson-Edell, K.A., Liu, S., et al. MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation. Nat. Cell Biol. 17 (2015), 1049–1061.
65. Layer, J.P., Kronmüller, M.T., Quast, T., van den Boorn-Konijnenberg, D., Effern, M., Hinze, D., Althoff, K., Schramm, A., Westermann, F., Peifer, M., et al. Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression. OncoImmunology, 6, 2017, e1320626.
66. Le, D.T., Uram, J.N., Wang, H., Bartlett, B.R., Kemberling, H., Eyring, A.D., Skora, A.D., Luber, B.S., Azad, N.S., Laheru, D., et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N. Engl. J. Med. 372 (2015), 2509–2520.
67. Lennerz, V., Fatho, M., Gentilini, C., Frye, R.A., Lifke, A., Ferel, D., Wölfel, C., Huber, C., Wölfel, T., The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc. Natl. Acad. Sci. USA 102 (2005), 16013–16018.
68. Lesina, M., Wörmann, S.M., Morton, J., Diakopoulos, K.N., Korneeva, O., Wimmer, M., Einwächter, H., Sperveslage, J., Demir, I.E., Kehl, T., et al. RelA regulates CXCL1/CXCR2-dependent oncogene-induced senescence in murine Kras-driven pancreatic carcinogenesis. J. Clin. Invest. 126 (2016), 2919–2932.
69. Linnemann, C., van Buuren, M.M., Bies, L., Verdegaal, E.M., Schotte, R., Calis, J.J., Behjati, S., Velds, A., Hilkmann, H., Atmioui, D.E., et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat. Med. 21 (2015), 81–85.
70. + regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Res. Treat. 130 (2011), 645–655.
71. Lujambio, A., Akkari, L., Simon, J., Grace, D., Tschaharganeh, D.F., Bolden, J.E., Zhao, Z., Thapar, V., Joyce, J.A., Krizhanovsky, V., Lowe, S.W., Non-cell-autonomous tumor suppression by p53. Cell 153 (2013), 449–460.
72. Medrek, C., Pontén, F., Jirström, K., Leandersson, K., The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer, 12, 2012, 306.
73. Meylan, E., Dooley, A.L., Feldser, D.M., Shen, L., Turk, E., Ouyang, C., Jacks, T., Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 462 (2009), 104–107.
74. Moody, S.E., Sarkisian, C.J., Hahn, K.T., Gunther, E.J., Pickup, S., Dugan, K.D., Innocent, N., Cardiff, R.D., Schnall, M.D., Chodosh, L.A., Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell 2 (2002), 451–461.
75. Muller, P.A., Vousden, K.H., Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell 25 (2014), 304–317.
76. Muñoz-Espín, D., Serrano, M., Cellular senescence: from physiology to pathology. Nat. Rev. Mol. Cell Biol. 15 (2014), 482–496.
77. Muñoz-Fontela, C., Mandinova, A., Aaronson, S.A., Lee, S.W., Emerging roles of p53 and other tumour-suppressor genes in immune regulation. Nat. Rev. Immunol. 16 (2016), 741–750.
78. Ock, C.Y., Hwang, J.E., Keam, B., Kim, S.B., Shim, J.J., Jang, H.J., Park, S., Sohn, B.H., Cha, M., Ajani, J.A., et al. Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. Nat. Commun., 8, 2017, 1050.
79. Parker, J.S., Mullins, M., Cheang, M.C., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27 (2009), 1160–1167.
80. Peng, W., Chen, J.Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M.T., Xu, C., McKenzie, J.A., Zhang, C., Liang, X., et al. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 6 (2016), 202–216.
81. Pérez-Mancera, P.A., Young, A.R., Narita, M., Inside and out: the activities of senescence in cancer. Nat. Rev. Cancer 14 (2014), 547–558.
82. Pribluda, A., Elyada, E., Wiener, Z., Hamza, H., Goldstein, R.E., Biton, M., Burstain, I., Morgenstern, Y., Brachya, G., Billauer, H., et al. A senescence-inflammatory switch from cancer-inhibitory to cancer-promoting mechanism. Cancer Cell 24 (2013), 242–256.
83. Pylayeva-Gupta, Y., Lee, K.E., Hajdu, C.H., Miller, G., Bar-Sagi, D., Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 21 (2012), 836–847.
84. Quigley, D., Silwal-Pandit, L., Dannenfelser, R., Langerød, A., Vollan, H.K., Vaske, C., Siegel, J.U., Troyanskaya, O., Chin, S.F., Caldas, C., et al. Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53. Mol. Cancer Res. 13 (2015), 493–501.
85. Rizvi, N.A., Hellmann, M.D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J.J., Lee, W., Yuan, J., Wong, P., Ho, T.S., et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348 (2015), 124–128.
86. Robbins, P.F., Lu, Y.C., El-Gamil, M., Li, Y.F., Gross, C., Gartner, J., Lin, J.C., Teer, J.K., Cliften, P., Tycksen, E., et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 19 (2013), 747–752.
87. Robinson, D.R., Wu, Y.M., Lonigro, R.J., Vats, P., Cobain, E., Everett, J., Cao, X., Rabban, E., Kumar-Sinha, C., Raymond, V., et al. Integrative clinical genomics of metastatic cancer. Nature 548 (2017), 297–303.
88. Rooney, M.S., Shukla, S.A., Wu, C.J., Getz, G., Hacohen, N., Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160 (2015), 48–61.
89. Rous, P., A Sarcoma of the Fowl Transmissible by an Agent Separable from the Tumor Cells. J. Exp. Med. 13 (1911), 397–411.
90. Sagiv-Barfi, I., Kohrt, H.E., Czerwinski, D.K., Ng, P.P., Chang, B.Y., Levy, R., Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proc. Natl. Acad. Sci. USA 112 (2015), E966–E972.
91. Sarkar, S., Bristow, C.A., Dey, P., Rai, K., Perets, R., Ramirez-Cardenas, A., Malasi, S., Huang-Hobbs, E., Haemmerle, M., Wu, S.Y., et al. PRKCI promotes immune suppression in ovarian cancer. Genes Dev. 31 (2017), 1109–1121.
92. Savas, P., Salgado, R., Denkert, C., Sotiriou, C., Darcy, P.K., Smyth, M.J., Loi, S., Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat. Rev. Clin. Oncol. 13 (2016), 228–241.
93. Schumacher, T.N., Schreiber, R.D., Neoantigens in cancer immunotherapy. Science 348 (2015), 69–74.
94. Schuster, C., Berger, A., Hoelzl, M.A., Putz, E.M., Frenzel, A., Simma, O., Moritz, N., Hoelbl, A., Kovacic, B., Freissmuth, M., et al. The cooperating mutation or “second hit” determines the immunologic visibility toward MYC-induced murine lymphomas. Blood 118 (2011), 4635–4645.
95. Schwitalla, S., Ziegler, P.K., Horst, D., Becker, V., Kerle, I., Begus-Nahrmann, Y., Lechel, A., Rudolph, K.L., Langer, R., Slotta-Huspenina, J., et al. Loss of p53 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph node metastasis of carcinogen-induced colorectal tumors. Cancer Cell 23 (2013), 93–106.
96. Shchors, K., Shchors, E., Rostker, F., Lawlor, E.R., Brown-Swigart, L., Evan, G.I., The Myc-dependent angiogenic switch in tumors is mediated by interleukin 1beta. Genes Dev. 20 (2006), 2527–2538.
97. Shen, Q., Cohen, B., Zheng, W., Rahbar, R., Martin, B., Murakami, K., Lamorte, S., Thompson, P., Berman, H., Zúñiga-Pflücker, J.C., et al. Notch Shapes the Innate Immunophenotype in Breast Cancer. Cancer Discov. 7 (2017), 1320–1335.
98. Shin, D.S., Zaretsky, J.M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C.S., Hugo, W., Sandoval, S., Torrejon, D.Y., et al. Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. Cancer Discov. 7 (2017), 188–201.
99. Sodir, N.M., Swigart, L.B., Karnezis, A.N., Hanahan, D., Evan, G.I., Soucek, L., Endogenous Myc maintains the tumor microenvironment. Genes Dev. 25 (2011), 907–916.
100. Soucek, L., Lawlor, E.R., Soto, D., Shchors, K., Swigart, L.B., Evan, G.I., Mast cells are required for angiogenesis and macroscopic expansion of Myc-induced pancreatic islet tumors. Nat. Med. 13 (2007), 1211–1218.
101. Sparmann, A., Bar-Sagi, D., Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 6 (2004), 447–458.
102. Spranger, S., Bao, R., Gajewski, T.F., Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature 523 (2015), 231–235.
103. Spranger, S., Luke, J.J., Bao, R., Zha, Y., Hernandez, K.M., Li, Y., Gajewski, A.P., Andrade, J., Gajewski, T.F., Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma. Proc. Natl. Acad. Sci. USA 113 (2016), E7759–E7768.
104. Stanton, S.E., Adams, S., Disis, M.L., Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: A Systematic Review. JAMA Oncol. 2 (2016), 1354–1360.
105. Stehelin, D., Varmus, H.E., Bishop, J.M., Vogt, P.K., DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature 260 (1976), 170–173.
106. Stewart, T.A., Pattengale, P.K., Leder, P., Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes. Cell 38 (1984), 627–637.
107. Stiff, A., Trikha, P., Wesolowski, R., Kendra, K., Hsu, V., Uppati, S., McMichael, E., Duggan, M., Campbell, A., Keller, K., et al. Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment. Cancer Res. 76 (2016), 2125–2136.
108. Stodden, G.R., Lindberg, M.E., King, M.L., Paquet, M., MacLean, J.A., Mann, J.L., DeMayo, F.J., Lydon, J.P., Hayashi, K., Loss of Cdh1 and Trp53 in the uterus induces chronic inflammation with modification of tumor microenvironment. Oncogene 34 (2015), 2471–2482.
109. Topper, M.J., Vaz, M., Chiappinelli, K.B., DeStefano Shields, C.E., Niknafs, N., Yen, R.C., Wenzel, A., Hicks, J., Ballew, M., Stone, M., et al. Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer. Cell 171 (2017), 1284–1300 e1221.
110. Toso, A., Revandkar, A., Di Mitri, D., Guccini, I., Proietti, M., Sarti, M., Pinton, S., Zhang, J., Kalathur, M., Civenni, G., et al. Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity. Cell Rep. 9 (2014), 75–89.
111. Van Allen, E.M., Miao, D., Schilling, B., Shukla, S.A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Foppen, M.H.G., Goldinger, S.M., et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350 (2015), 207–211.
112. van Rooij, N., van Buuren, M.M., Philips, D., Velds, A., Toebes, M., Heemskerk, B., van Dijk, L.J., Behjati, S., Hilkmann, H., El Atmioui, D., et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J. Clin. Oncol. 31 (2013), e439–e442.
113. Vanden Borre, P., Gunda, V., McFadden, D.G., Sadow, P.M., Varmeh, S., Bernasconi, M., Parangi, S., Combined BRAF(V600E)- and SRC-inhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer. Oncotarget 5 (2014), 3996–4010.
114. Ventura, A., Kirsch, D.G., McLaughlin, M.E., Tuveson, D.A., Grimm, J., Lintault, L., Newman, J., Reczek, E.E., Weissleder, R., Jacks, T., Restoration of p53 function leads to tumour regression in vivo. Nature 445 (2007), 661–665.
115. von Hansemann, D., Ueber asymmetrische Zelltheilung in Epithelkrebsen und deren biologische Bedeutung. Virchows Arch. Path. Anat 119 (1890), 299–326.
116. Wang, G., Lu, X., Dey, P., Deng, P., Wu, C.C., Jiang, S., Fang, Z., Zhao, K., Konaparthi, R., Hua, S., et al. Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression. Cancer Discov. 6 (2016), 80–95.
117. Wang, Q., Hu, B., Hu, X., Kim, H., Squatrito, M., Scarpace, L., deCarvalho, A.C., Lyu, S., Li, P., Li, Y., et al. Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. Cancer Cell 32 (2017), 42–56 e46.
118. Welte, T., Kim, I.S., Tian, L., Gao, X., Wang, H., Li, J., Holdman, X.B., Herschkowitz, J.I., Pond, A., Xie, G., et al. Oncogenic mTOR signalling recruits myeloid-derived suppressor cells to promote tumour initiation. Nat. Cell Biol. 18 (2016), 632–644.
119. Wislez, M., Fujimoto, N., Izzo, J.G., Hanna, A.E., Cody, D.D., Langley, R.R., Tang, H., Burdick, M.D., Sato, M., Minna, J.D., et al. High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras. Cancer Res. 66 (2006), 4198–4207.
120. Wölfel, T., Hauer, M., Schneider, J., Serrano, M., Wölfel, C., Klehmann-Hieb, E., De Plaen, E., Hankeln, T., Meyer zum Büschenfelde, K.H., Beach, D., A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269 (1995), 1281–1284.
121. Wörmann, S.M., Song, L., Ai, J., Diakopoulos, K.N., Kurkowski, M.U., Görgülü K., Ruess, D., Campbell, A., Doglioni, C., Jodrell, D., et al. Loss of P53 Function Activates JAK2-STAT3 Signaling to Promote Pancreatic Tumor Growth, Stroma Modification, and Gemcitabine Resistance in Mice and Is Associated With Patient Survival. Gastroenterology 151 (2016), 180–193.e12.
122. Xue, W., Zender, L., Miething, C., Dickins, R.A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., Lowe, S.W., Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445 (2007), 656–660.
123. Yang, Y., Cancer immunotherapy: harnessing the immune system to battle cancer. J. Clin. Invest. 125 (2015), 3335–3337.
124. Yetil, A., Anchang, B., Gouw, A.M., Adam, S.J., Zabuawala, T., Parameswaran, R., van Riggelen, J., Plevritis, S., Felsher, D.W., p19ARF is a critical mediator of both cellular senescence and an innate immune response associated with MYC inactivation in mouse model of acute leukemia. Oncotarget 6 (2015), 3563–3577.
125. Ying, H., Elpek, K.G., Vinjamoori, A., Zimmerman, S.M., Chu, G.C., Yan, H., Fletcher-Sananikone, E., Zhang, H., Liu, Y., Wang, W., et al. PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB-cytokine network. Cancer Discov. 1 (2011), 158–169.